Wolverine Trading
IMUC

Wolverine Trading’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Wolverine Trading’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,250
Closed -$6K – 5780
2016
Q3 		$6K Buy
+1,250
New +$8.04K ﹤0.01% 4548

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wolverine Trading's IMUC Position: Q4 2016 in Review

Wolverine Trading sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 1,250 shares — an estimated $6K sold.

Wolverine Trading first reported a position in IMUC in Q3 2016 and held it in 1 quarter. The position peaked at $6K in Q3 2016. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Wolverine Trading reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Wolverine Trading sold 1,250 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $6K.
  • Wolverine Trading first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2016 and held it in 1 quarter.
  • Wolverine Trading's ImmunoCellular Therapeutics, Ltd. position peaked at $6K in Q3 2016.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Wolverine Trading's 13F filing for Q4 2016, filed 14 Feb 2017.